PUBLISHER: DataM Intelligence | PRODUCT CODE: 1268937
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1268937
The global oral transmucosal drugs market reached US$ 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 24,441.4 million by 2030. The oral transmucosal drugs market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).
Globally, chronic or non-communicable diseases are on the rise and are responsible for 73% of all fatalities. Non-communicable illnesses are to blame for 44% of lost disability-adjusted life years and 53% of all fatalities in India. More than a sixth of the world's people reside in India, which has been experiencing significant socio-economic development and an epidemiological trend towards chronic non-communicable diseases led to the rise in the oral transmucosal drugs market growth.
The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in the need for alternative routes of administration of drugs for end-of-life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. The factors such as growing cases of autoimmune disorders, technological advancements, and oral drugs market developments are boosting the global oral transmucosal drugs market growth.
For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the U.S., and compiles the most recent data on population-based cancer occurrence and outcomes. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths were projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer. Thus, the prevelance of cancer boost the market growth.
Transmucosal drug delivery is preferable to oral and parenteral forms of administration since it is non-invasive and enables self-administration or administration by trained carers. Understanding the mechanism of mucosal drug absorption is crucial in order to find medications that are right for transmucosal administration. The intranasal, oral, and rectal mucosa each have particular morphological and physiological traits, but they also have several things in common.
Due to supply chain disruption, a government-imposed lockdown, manpower shortages, and limitations on manufacturing activities, the COVID-19 pandemic had a short-term detrimental effect on the market for oral transmucosal medications. Oral transmucosal medication producers, on the other hand, are profiting from coronavirus outbreaks by providing reduced first-pass metabolism with a quick onset of action. These qualities make oral transmucosal medications useful for palliative care and end-of-life care to provide quick symptom alleviation. Since some patients' health has a tendency to rapidly decline in some circumstances, it was essential during the COVID-19 pandemic.
The Russia-Ukraine is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is anticipated to have little influence over the global oral transmucosal drugs market over the forecast period.
Artificial intelligence (AI) has become more prevalent in a number of societal fields, most notably the pharmaceutical industry. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution are more versatile, thanks to wireless connections.
The global oral transmucosal drugs market is segmented based on product type, indication, route of administartion, distribution channel, and region.
The opioid dependence segment is estimated to hold a majority of the oral transmucosal drugs market share during the forecast period.
The opioid dependence indication holds about 39.6% of the total oral transmucosal drugs market. The growing cases of opioid overdose is driving the segment growth. For instance, according to the World Health Organization 2021, globally about 0.5 million deaths are caused because of drug abuse. Over 70% of these deaths are associated with opioids, accounting for over 30% of those drug overdose deaths.
Moreover, prescribing of opioids in the Canada and U.S. has caused high rates of unacceptable death rates, prescription opioid abuse, and an immense obligation to the affected communities.
Europe is estimated to hold the second-largest share of the global oral transmucosal drugs market during the forecast period.
The Europe region holds the second largest share of the global oral transmucosal drugs market accounting for approximately 29%. The market in the Europe region is being driven by the rising demand for pain management and active regional market participants.
For instance, Aquestive Therapeutics, Inc., a pharmaceutical company that develops drugs to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced in September 2022 that it entered a license and supply agreement for Libervant (diazepam) Buccal Film with Pharmanovia. This agreement will allow Pharmanovia to market Libervant (diazepam) Buccal Film in the European Union, the UK, and other countries.
The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.
The global oral transmucosal drugs market report would provide approximately 53 tables, 54figures, and 195 pages.
LIST NOT EXHAUSTIVE